戻る Agenda
Virtual Clinical Trials
Session Chair(s)
Nechama Katan, MA, MS
Director, Statistical Programming
Pfizer Inc, United States
The term decentralized trial is not something new. However, it is becoming more mainstream as patients are more willing to participate in a clinical trial when there is less patient burden. By removing barriers of trial participation, patients are more likely to be compliant, more likely to be retained, and more likely to complete the trial. Key lessons learned will be discussed as well as pitfalls to avoid in the future. What went well, what was more challenging than expected, where were the surprises.
Learning Objective : Discuss key lessons learned about decentralized trials; Describe pitfalls to avoid.
Speaker(s)
Building Connections and Building Blocks for eSource: eCOA and ePRO are the Building Blocks to Decentralized Trials
Alison Holland
Medable, United States
Executive General Manager, Digital and Decentralized Solutions
A Case Study in Applying Risk-Based Monitoring Analytics to a Fully Virtual Trial
Nechama Katan, MA, MS
Pfizer Inc, United States
Director, Statistical Programming